4//SEC Filing
Lippis Daniel J. 4
Accession 0001225208-25-009934
CIK 0001099800other
Filed
Dec 11, 7:00 PM ET
Accepted
Dec 12, 5:57 PM ET
Size
8.8 KB
Accession
0001225208-25-009934
Insider Transaction Report
Form 4
Lippis Daniel J.
CVP, TAVR
Transactions
- Exercise/Conversion
Common Stock
2025-12-12$59.26/sh+1,019$60,383→ 23,020.91 total - Sale
Common Stock
2025-12-12$84.03/sh−1,019$85,625→ 22,001.91 total - Exercise/Conversion
Employee Stock Option (Right to Acquire)
2025-12-12−1,019→ 5,095 totalExercise: $59.26From: 2020-05-08Exp: 2026-05-07→ Common Stock (1,019 underlying)
Footnotes (2)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025.
- [F2]This transaction was executed in multiple trades at prices ranging from $83.58 to $84.46. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Documents
Issuer
Edwards Lifesciences Corp
CIK 0001099800
Entity typeother
Related Parties
1- filerCIK 0002004380
Filing Metadata
- Form type
- 4
- Filed
- Dec 11, 7:00 PM ET
- Accepted
- Dec 12, 5:57 PM ET
- Size
- 8.8 KB